Bain Capital is reportedly aiming to raise at least $7bn for its upcoming Bain Capital Asia Fund VI, with plans to commence fundraising at the end of April 2025, surpassing the $4bn raised for its previous Asia-focused fund, according to a report by Bloomberg.
In addition to its main Asia fund, Bain Capital has been actively raising capital for its Bain Capital Special Situations Asia Fund III since November 2024, with a goal of securing at least $2.1bnn. Discussions are ongoing with major asset allocators regarding separately managed accounts tailored to specific investor needs, with expectations of a first closing within weeks.​
The firm has a significant presence in Asia, having invested in companies such as Emcure Pharmaceuticals and CitiusTech Healthcare Technology in India, and acquiring a 60% stake in York Holdings and medical firm Mitsubishi Tanabe Pharma in Japan. ​
Despite a slowdown in private equity fundraising in Asia, with total capital raised falling to approximately $50bn in 2024 from nearly $187bn in 2021, Bain Capital continues to attract substantial investments. The firm’s latest fundraising efforts come amid global economic uncertainties, including geopolitical tensions and market volatility. ​
Other prominent fund managers, such as EQT AB, are also actively seeking significant capital, with EQT aiming to raise $12.5bn for its next Asia fund, which would be one of the largest private equity pools in the region. ​
However, recent policy changes, including new tariff implementations, have led investment managers to reassess their strategies, resulting in a more cautious approach to dealmaking as they evaluate market conditions.
